573 related articles for article (PubMed ID: 34815355)
1. Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer.
Nalawade SA; Shafer P; Bajgain P; McKenna MK; Ali A; Kelly L; Joubert J; Gottschalk S; Watanabe N; Leen A; Parihar R; Vera Valdes JF; Hoyos V
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34815355
[TBL] [Abstract][Full Text] [Related]
2. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.
Parihar R; Rivas C; Huynh M; Omer B; Lapteva N; Metelitsa LS; Gottschalk SM; Rooney CM
Cancer Immunol Res; 2019 Mar; 7(3):363-375. PubMed ID: 30651290
[TBL] [Abstract][Full Text] [Related]
3. An In Vitro Comparison of Costimulatory Domains in Chimeric Antigen Receptor T Cell for Breast Cancer Treatment.
Khuisangeam N; Jewmoung S; Thaiwong R; Tudsamran S; Hirankarn N; Suppipat K; Tawinwung S
J Immunol Res; 2022; 2022():2449373. PubMed ID: 36457849
[TBL] [Abstract][Full Text] [Related]
4. Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2
Priceman SJ; Tilakawardane D; Jeang B; Aguilar B; Murad JP; Park AK; Chang WC; Ostberg JR; Neman J; Jandial R; Portnow J; Forman SJ; Brown CE
Clin Cancer Res; 2018 Jan; 24(1):95-105. PubMed ID: 29061641
[No Abstract] [Full Text] [Related]
5. Secretion of 4-1BB Ligand Crosslinked to PD-1 Checkpoint Inhibitor Potentiates Chimeric Antigen Receptor T Cell Solid Tumor Efficacy.
Dunn ZS; Qu Y; MacMullan M; Chen X; Cinay G; Wang P
Hum Gene Ther; 2023 Nov; 34(21-22):1145-1161. PubMed ID: 36851890
[TBL] [Abstract][Full Text] [Related]
6. Repression of MUC1 Promotes Expansion and Suppressive Function of Myeloid-Derived Suppressor Cells in Pancreatic and Breast Cancer Murine Models.
Sahraei M; Bose M; Sanders JA; De C; DasRoy L; Nath S; Brouwer CR; Mukherjee P
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070449
[TBL] [Abstract][Full Text] [Related]
7. Chimeric antigen receptor modified T cell (CAR-T) co-expressed with ICOSL-41BB promote CAR-T proliferation and tumor rejection.
Hu W; Huang X; Huang X; Chen W; Hao L; Chen Z
Biomed Pharmacother; 2019 Oct; 118():109333. PubMed ID: 31545280
[TBL] [Abstract][Full Text] [Related]
8. Orthotopic and Heterotopic Murine Models of Pancreatic Cancer Exhibit Different Immunological Microenvironments and Different Responses to Immunotherapy.
Wang J; Liu X; Ji J; Luo J; Zhao Y; Zhou X; Zheng J; Guo M; Liu Y
Front Immunol; 2022; 13():863346. PubMed ID: 35874730
[TBL] [Abstract][Full Text] [Related]
9. Olaparib Suppresses MDSC Recruitment via SDF1α/CXCR4 Axis to Improve the Anti-tumor Efficacy of CAR-T Cells on Breast Cancer in Mice.
Sun R; Luo H; Su J; Di S; Zhou M; Shi B; Sun Y; Du G; Zhang H; Jiang H; Li Z
Mol Ther; 2021 Jan; 29(1):60-74. PubMed ID: 33010818
[TBL] [Abstract][Full Text] [Related]
10. CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation.
Bajgain P; Tawinwung S; D'Elia L; Sukumaran S; Watanabe N; Hoyos V; Lulla P; Brenner MK; Leen AM; Vera JF
J Immunother Cancer; 2018 May; 6(1):34. PubMed ID: 29747685
[TBL] [Abstract][Full Text] [Related]
11. FAP-targeted CAR-T suppresses MDSCs recruitment to improve the antitumor efficacy of claudin18.2-targeted CAR-T against pancreatic cancer.
Liu Y; Sun Y; Wang P; Li S; Dong Y; Zhou M; Shi B; Jiang H; Sun R; Li Z
J Transl Med; 2023 Apr; 21(1):255. PubMed ID: 37046312
[TBL] [Abstract][Full Text] [Related]
12. IL15 modification enables CAR T cells to act as a dual targeting agent against tumor cells and myeloid-derived suppressor cells in GBM.
Zannikou M; Duffy JT; Levine RN; Seblani M; Liu Q; Presser A; Arrieta VA; Chen CJ; Sonabend AM; Horbinski CM; Lee-Chang C; Miska J; Lesniak MS; Gottschalk S; Balyasnikova IV
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36759014
[TBL] [Abstract][Full Text] [Related]
13. GPC3-IL7-CCL19-CAR-T primes immune microenvironment reconstitution for hepatocellular carcinoma therapy.
Lu LL; Xiao SX; Lin ZY; Bai JJ; Li W; Song ZQ; Zhou YH; Lu B; Wu WZ
Cell Biol Toxicol; 2023 Dec; 39(6):3101-3119. PubMed ID: 37853185
[TBL] [Abstract][Full Text] [Related]
14. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF
J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862
[TBL] [Abstract][Full Text] [Related]
15. CXCR4-modified CAR-T cells suppresses MDSCs recruitment via STAT3/NF-κB/SDF-1α axis to enhance efficacy against pancreatic cancer.
Sun R; Sun Y; Wu C; Liu Y; Zhou M; Dong Y; Du G; Luo H; Shi B; Jiang H; Li Z
Mol Ther; 2023 Nov; 31(11):3193-3209. PubMed ID: 37735875
[TBL] [Abstract][Full Text] [Related]
16. CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth.
Zhou R; Yazdanifar M; Roy LD; Whilding LM; Gavrill A; Maher J; Mukherjee P
Front Immunol; 2019; 10():1149. PubMed ID: 31178870
[TBL] [Abstract][Full Text] [Related]
17. Optimized CAR-T therapy based on spatiotemporal changes and chemotactic mechanisms of MDSCs induced by hypofractionated radiotherapy.
Zhang B; Hu M; Ma Q; Li K; Li X; He X; Shu P; Chen Y; Gao G; Qin D; Guo F; Zhao J; Liu N; Zhou K; Feng M; Liao W; Li D; Wang X; Wang Y
Mol Ther; 2023 Jul; 31(7):2105-2119. PubMed ID: 37073129
[TBL] [Abstract][Full Text] [Related]
18. Novel role of microphthalmia-associated transcription factor in modulating the differentiation and immunosuppressive functions of myeloid-derived suppressor cells.
Lee A; Park H; Lim S; Lim J; Koh J; Jeon YK; Yang Y; Lee MS; Lim JS
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36627143
[TBL] [Abstract][Full Text] [Related]
19. Visualization and quantification of
Hoffmann SHL; Reck DI; Maurer A; Fehrenbacher B; Sceneay JE; Poxleitner M; Öz HH; Ehrlichmann W; Reischl G; Fuchs K; Schaller M; Hartl D; Kneilling M; Möller A; Pichler BJ; Griessinger CM
Theranostics; 2019; 9(20):5869-5885. PubMed ID: 31534525
[TBL] [Abstract][Full Text] [Related]
20. CD28 and 41BB Costimulatory Domains Alone or in Combination Differentially Influence Cell Surface Dynamics and Organization of Chimeric Antigen Receptors and Early Activation of CAR T Cells.
Mezősi-Csaplár M; Szöőr Á; Vereb G
Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]